

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
07 August 2025 (07.08.2025)



(10) International Publication Number
WO 2025/163082 A1

(51) International Patent Classification:
A61K 51/08 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/EP2025/052422

(22) International Filing Date:
30 January 2025 (30.01.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/627,705 31 January 2024 (31.01.2024) US
63/550,951 07 February 2024 (07.02.2024) US
24305751.0 14 May 2024 (14.05.2024) EP
24306567.9 25 September 2024 (25.09.2024) EP
24306765.9 21 October 2024 (21.10.2024) EP

(71) Applicants: **MOLECULAR PARTNERS AG** [CH/CH];
Wagistrasse 14, 8952 Zürich-Schlieren (CH). **ORANO
MED THERANOSTICS** [FR/FR]; 125 avenue de Paris,
92320 Châtillon (FR).

(72) Inventors; and

(71) Applicants: **SAIDI, Amal** [FR/FR]; c/o Orano Med Theranostics, 125 avenue de Paris, 92320 Châtillon (FR).
SCHATZMANN, Aaron [US/FR]; c/o Orano Med Theranostics, 125 avenue de Paris, 92320 Châtillon (FR).
TORGUE, Julien [FR/FR]; c/o Orano Med Theranostics, 125 avenue de Paris, 92320 Châtillon (FR).

(72) Inventors: **REICHEN, Christian**; c/o Molecular Partners AG, Wagistrasse 14, 8952 Zürich-Schlieren (CH).
MALVEZZI, Francesca; c/o Molecular Partners AG, Wagistrasse 14, 8952 Schlieren (CH). **CROSET, Amelie**; c/o Molecular Partners AG, Wagistrasse 14, 8952 Zürich-Schlieren (CH). **RIESENBERG, Stefanie**; c/o Molecular Partners AG, Wagistrasse 14, 8952 Zürich-Schlieren (CH).

(74) Agent: **VOSSIUS & PARTNER (NO 31)**; Patentanwälte Rechtsanwälte mbB, Siebertstrasse 3, 81675 München (DE).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,

KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: DLL3-SPECIFIC BINDING CONSTRUCTS AND THEIR USE IN RADIOTHERAPY

(57) Abstract: The present invention relates to DLL3-specific binding constructs comprising a designed ankyrin repeat domain with binding specificity for DLL3, a connector, and a chelator capable of bonding to a radionuclide, such as Pb-212, as well as to such DLL3-specific binding constructs comprising a half-life extending moiety with binding specificity for serum albumin. The invention further relates to methods of producing such radio-labelled DLL3-specific binding constructs, pharmaceutical compositions comprising such constructs, and the use of such constructs or pharmaceutical compositions in methods for treating, imaging or diagnosing diseases, such as cancer.



WO 2025/163082 A1